Mn Services Vermogensbeheer B.V. Sells 1,200 Shares of Thermo Fisher Scientific Inc. $TMO

Key Points

• Mn Services Vermogensbeheer B.V. has reduced its stake in Thermo Fisher Scientific Inc. by 0.8%, now owning 141,100 shares valued at approximately $57.2 million.
• Analysts show mixed sentiments on TMO, with Robert W. Baird raising the price target to $567 and HSBC setting a $510 target, while the company maintains a Moderate Buy consensus rating.
• Thermo Fisher recently reported earnings of $5.36 EPS, exceeding expectations, and declared a quarterly dividend of $0.43, reflecting a 0.4% dividend yield.

Mn Services Vermogensbeheer B.V. decreased its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 0.8% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 141,100 shares of the medical research company's stock after selling 1,200 shares during the period. Mn Services Vermogensbeheer B.V.'s holdings in Thermo Fisher Scientific were worth $57,210,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of the company. Bernard Wealth Management Corp. bought a new position in Thermo Fisher Scientific during the fourth quarter valued at about $25,000. CBIZ Investment Advisory Services LLC increased its stake in shares of Thermo Fisher Scientific by 137.5% in the first quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company's stock worth $28,000 after purchasing an additional 33 shares during the period. Ameriflex Group Inc. bought a new position in shares of Thermo Fisher Scientific in the fourth quarter worth about $30,000. Anderson Financial Strategies LLC bought a new position in shares of Thermo Fisher Scientific in the first quarter worth about $30,000. Finally, Keystone Global Partners LLC bought a new position in shares of Thermo Fisher Scientific in the first quarter worth about $31,000. Institutional investors and hedge funds own 89.23% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have recently commented on TMO. Barclays upgraded Thermo Fisher Scientific from an "equal weight" rating to an "overweight" rating and lifted their price objective for the stock from $490.00 to $550.00 in a research note on Thursday, September 11th. William Blair started coverage on Thermo Fisher Scientific in a research note on Monday, August 18th. They issued an "outperform" rating on the stock. Royal Bank Of Canada set a $561.00 price target on Thermo Fisher Scientific and gave the company an "outperform" rating in a research note on Tuesday, September 2nd. UBS Group boosted their price target on Thermo Fisher Scientific from $460.00 to $500.00 and gave the company a "neutral" rating in a research note on Thursday, July 24th. Finally, Wall Street Zen lowered Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a research note on Sunday, September 7th. Sixteen investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat, Thermo Fisher Scientific presently has an average rating of "Moderate Buy" and an average price target of $588.35.

Insider Buying and Selling

In related news, CAO Joseph R. Holmes sold 385 shares of the business's stock in a transaction that occurred on Friday, August 29th. The shares were sold at an average price of $492.63, for a total value of $189,662.55. Following the completion of the transaction, the chief accounting officer owned 2,319 shares in the company, valued at $1,142,408.97. The trade was a 14.24% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Gianluca Pettiti sold 400 shares of the company's stock in a transaction on Friday, July 25th. The shares were sold at an average price of $479.98, for a total transaction of $191,992.00. Following the sale, the executive vice president owned 22,367 shares of the company's stock, valued at $10,735,712.66. The trade was a 1.76% decrease in their position. The disclosure for this sale can be found here. Insiders sold 30,066 shares of company stock worth $14,182,963 in the last quarter. Insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Price Performance

Shares of TMO traded down $5.04 on Monday, hitting $474.54. The company's stock had a trading volume of 2,352,185 shares, compared to its average volume of 1,557,193. The company has a market capitalization of $179.19 billion, a PE ratio of 27.45, a PEG ratio of 2.56 and a beta of 0.75. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50. Thermo Fisher Scientific Inc. has a fifty-two week low of $385.46 and a fifty-two week high of $623.77. The company has a 50 day moving average price of $472.99 and a 200 day moving average price of $448.55.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, topping the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The firm had revenue of $10.86 billion during the quarter, compared to analysts' expectations of $10.68 billion. During the same quarter in the previous year, the company posted $5.37 EPS. Thermo Fisher Scientific's revenue was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 0.4%. The ex-dividend date is Monday, September 15th. Thermo Fisher Scientific's payout ratio is 9.95%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.